KEYTRUDA 25 mg/mL concentrate for solution for infusion, ATL001 clinical trials

An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer

This study is looking at a new treatment for advanced lung cancer. It combines a special cell therapy (ATL001) with existing treatments like KEYTRUDA. The main goal is to check how safe these treatments are and if they help shrink tumours. It's for adults with non-small cell lung cancer.